Early gastric cancer
Conditions
Interventions
None listed
Sponsors
Tohoku University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who were enrolled in the Tohoku GI study (UMIN000023385) (registration: 2016-2019) and those in whom informed consent for participating in this study are acquired will be enrolled in this study. The inclusion and exclusion criteria for that study are as follows. <Inclusion criteria in a study of UMIN000023385> 1. Patients with first early gastric cancers which will be treated by ESD 2. Patients with 0-2 of performance status (PS) in an Eastern Cooperative Oncology Group (ECOG) criteria 3. Patients agreeing with the participation of this study <Inclusion criteria in a study of UMIN000023385> 1. Patients with a history of endoscopic resection for early gastric cancers 2. Patients with a history or a plan of gastrectomy 3. Patients with a history or a plan of chemotherapy for gastric cancers 4. Patients with a history or a plan of surgery, chemotherapy, or radiation therapy for esophageal cancers 5. Patients with a history of chemotherapy for malignant tumors excluding gastric or esophageal cancers within 5 years 6. Patients with malignant tumors except for gastric or esophageal cancers who have a plan for endocrine therapy, chemotherapy, or radiation at the time of enrollment 7. Patients with early gastric cancers which did not meet the curative resection for ESD in the guidelines 8. Patients with gastric lesions diagnosed as Group 4 in the preoperative diagnosis resulting as no cancer in the pathological diagnosis of ESD specimen 9. Patients with pregnancy or breast-feeding 10. Patients with severe psychiatric disease 11. Patients regard as inappropriate for enrollment by the researcher 12. Patients whose serum creatinine level are 2.0 mg/dL or more 13. Patients who cannot understand Japanese language
Exclusion criteria
Exclusion criteria: None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The relationship between CYP2A6 polymorphism and multiple gastric cancers | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The relationship among CYP2A6 polymorphism, the amount of smoking, duration of smoking, and metachronous gastric cancers 2. The relationship among CYP2A6 polymorphism, the amount of smoking, duration of smoking, and metachronous gastric cancers 3. The relationship among CYP2A6 polymorphism, the amount of smoking, duration of smoking, and metachronous gastric cancers 4. The relationship between the duration of cessation and metachronous gastric cancers in each CYP2A6 polymorphism 5. The relationship between CYP2E1 polymorphism and multiple gastric cancers 6. The relationship among CYP2E1 polymorphism, the amount of drinking, duration of drinking, and multiple gastric cancers 7. The relationship among CYP2E1 polymorphism, the amount of drinking, duration of drinking, and synchronous gastric cancers 8. The relationship among CYP2E1 polymorphism, the amount of drinking, duration of drinking, and metachronous gastric cancers 9. The relationship between the duration of abstinence and metachronous gastric cancers in each CYP2E1 polymorphism 10. The relationship among ADH1B, ALDH2, and CYP2E1 polymorphisms, drinking, and multiple gastric cancers 11. The relationship among CYP2A6 and CYP2E1 polymorphisms, smoking, drinking, and esophageal cancers 12. The relationship between CEA and multiple gastric cancers | — |
Countries
Japan
Contacts
Public ContactWaku Hatta
Tohoku University Graduate School of Medicine Division of Gastroenterology
Outcome results
None listed